Ra Medical Systems Inc
F:4RM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ra Medical Systems Inc
F:4RM
|
US |
|
M
|
Mitsubishi UFJ Financial Group Inc
XMUN:MFZ
|
JP |
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IST:DGATE.E
|
TR |
|
D
|
Diageo PLC
XETRA:GUI
|
UK |
|
U
|
US Critical Metals Corp
OTC:USCMF
|
CA |
|
Elton International Trading Company SA
F:Y1O
|
GR |
|
F
|
First International Bank of Israel Ltd
TASE:FIBI
|
IL |
|
A
|
Avolta AG
XMUN:D2J
|
CH |
Earnings Calls
Last Earnings Call
Enrollment: Ra Medical said its pivotal atherectomy study reached 107 of 125 planned subjects, with management still targeting full enrollment by the end of Q3 2022 despite COVID-related delays.
Pipeline: The company said it remains on track for several regulatory milestones, including a 510(k) for DABRA 2.0 in Q3 2022 and a 510(k) for DABRA RX at the end of this year.
Strategy: Management disclosed that the board is reviewing strategic alternatives with an investment bank, citing the difficult capital-raising environment for micro-cap companies.
Results: Q1 revenue was just $9,000, while the company reported a net loss from continuing operations of $5.5 million, or $0.27 per share.
Cash: Ra Medical exited the quarter with $17.7 million of cash and cash equivalents after raising $9.7 million in a February public offering.
Leadership: CFO Andrew Jackson said he will resign later this quarter to become CFO of another company; the company is looking for an interim CFO.